Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Previously Presented) A nonapeptide selected from the group of peptides comprising the amino acid sequence of SEQ ID NO: 2, 3, 5, 8, 11, and 12 or a peptide with cytotoxic T cell inducibility, wherein one, two, or more amino acids have been substituted or added to the amino acid sequence of SEQ ID NO: 2, 3, 5, 8, 11, or 12.

2. (Cancelled)

3. (Previously Presented) The peptide of claim 1, wherein the second amino acid from the N terminus is phenylalanine, tyrosine, methionine, or tryptophan.

4. (Previously Presented) The peptide of claim 1 or 3, wherein the C-terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine.

5. (Previously Presented) A nonapeptide or decapeptide selected from the group of peptides comprising the amino acid sequence of SEQ ID NO: 29, 30, 33, 34, 40, ~~or~~ and 46 or a peptide with cytotoxic T cell inducibility, wherein one, two, or more amino acids have been substituted or added to the amino acid sequence of SEQ ID NO: 29, 30, 33, 34, 40, or 46.

6. (Cancelled)

7. (Previously Presented) The peptide of claim 5, wherein the second amino acid from the N terminus is leucine or methionine.

8. (Previously Presented) The peptide of claim 5 or 7, wherein the C-terminal amino acid is valine or leucine.

9. (Previously Presented) A pharmaceutical for treating and/or preventing tumors, wherein the pharmaceutical comprises one or more peptides of claim 1 or 5.

10. (Previously Presented) A pharmaceutical for treating diabetic retinopathy, chronic rheumatoid arthritis, psoriasis, and atherosclerosis, wherein the pharmaceutical comprises one or more peptides of claim 1 or 5.

11. (Previously Presented) An exosome that presents on its surface a complex comprising a peptide of claim 1 or 5, and an HLA antigen.

12. (Original) The exosome of claim 11, wherein the HLA antigen is HLA-A24 or HLA-A02.

13. (Original) The exosome of claim 12, wherein the HLA antigen is HLA-A2402 or HLA-0201.

14. (Previously Presented) A method for inducing an antigen-presenting cell with high cytotoxic T cell inducibility by using a peptide of claim 1 or 5.

15. (Previously Presented) A method for inducing a cytotoxic T cell by using a peptide of claim 1 or 5.

16. (Previously Presented) A method for inducing an antigen-presenting cell with high cytotoxic T cell inducibility, wherein said method comprises the step of introducing a gene that comprises a polynucleotide encoding a peptide of claim 1 or 5 into an antigen-presenting cell.

17. (Previously Presented) An isolated cytotoxic T cell that is induced by using a peptide of claim 1 or 5.

18. (Previously Presented) An antigen-presenting cell that presents a complex of an HLA antigen and a peptide of claim 1 or 5.

19. (Previously Presented) The antigen-presenting cell induced by the method of claim 14.

20. (Previously Presented) A vaccine for inhibiting angiogenesis at a diseased site, wherein the vaccine comprises a peptide of claim 1 or 5 as an active ingredient.

21. (Original) The vaccine of claim 20, which is used for administration to a subject whose HLA antigen is HLA-A24 or HLA-A02.

22. (Previously Presented) The vaccine of claim 20, which is used to suppress the growth and/or metastasis of malignant tumors.